The osteoporosis dilemma

Gynecological Endocrinology

Volumn 18, Issue 2, 2004, Pages 59-61

  Gambacciani, Marco ^a   Genazzani, Andrea R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PARATHYROID HORMONE; PHOSPHATE; RALOXIFENE; RECOMBINANT HORMONE; TIBOLONE;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON CANCER; DISEASE PREDISPOSITION; EDITORIAL; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; VERTEBRA FRACTURE;

DRUG APPROVAL; ESTROGEN REPLACEMENT THERAPY; EUROPE; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 1342347957     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590310001651812     Document Type: Editorial

References (17)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288:321-33
2. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
3. Cauley JA, Robbins J, Chen Z, et al; Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. J Am Med Assoc 2003;290:1729-38
4. Clemett D, Spencer CM. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 2000; 60:379-411
5. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637-45
6. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. J Am Med Assoc 1999;281:2189-97
7. Chlebowski Rt, Hendrix SL, Langer RD, et al.; Women's Health Initiative Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women' Health Initiative Randomized Trial. J Am Med Assoc 2003;289:3243-53
8. Genazzani AR, Gadducci A, Gambacciani M. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop, 9-12 June 2001, Opera del Duomo, Pisa, Italy. Climacteric 2001;4:181-93
9. Gambacciani M, Genazzani AR. The study with a million women (and hopefully fewer mistakes). Gynecol Endocrinol 2003;17:1-4
10. Genazzani AR, Gambacciani M. Controversial Issues In Climacteric Medicine (I). Cardiovascular Disease And Hormone Replacement Therapy, International Menopause Society Expert Workshop, 13-16 October 2000, Royal Society of Medicine, London, UK. Climacteric 2000;3:233-40
11. Genazzani AR, Gambacciani M. A personal initiative for women's health: to challenge the Women's Health Initiative. Gynecol Endocrinol 2002;16:255-7
12. Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxy-progesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-7
13. Utian W, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75: 1065-79
14. Gambacciani M, Ciaponi M, Cappagli M, Genazzani AR. Effects of low-dose, continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol 2001;185:1180-5
15. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effects of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. J Am Med Assoc 2002;287:2668-76
16. Gambacciani M, Genazzani AR. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas 2001;40:195-201
17. Gambacciani M, Genazzani AR. The missing R. Gynecol Endocrinol 2003;17:91-4